HEPZATO-KIT Sales Forecast, and Market Size Analysis – 2034
Description
Key Factors Driving HEPZATO-KIT Growth
1. First FDA-approved liver-directed therapy for metastatic uveal melanoma
HEPZATO KIT (melphalan with Hepatic Delivery System, HDS) received FDA approval in August 2023 for unresectable hepatic-dominant metastatic uveal melanoma (mUM).
It is the first and only liver-directed therapy approved specifically for this indication (Delcath press release, FDA approval notice).
First-mover advantage in a high unmet-need niche enables rapid adoption in specialized oncology centers.
Establishes strong positioning as a standard-of-care option for liver-dominant disease.
2. Strong clinical efficacy in liver metastases (primary disease driver)
In the pivotal FOCUS Phase III trial:
High response rates in the liver (key disease site) make HEPZATO particularly valuable →
Drives oncologist preference and clinical adoption.
3. Unique regional chemotherapy delivery system (HDS platform)
Uses a hepatic perfusion system to deliver high-dose melphalan directly to the liver, while filtering systemic circulation.
Allows higher local drug exposure with reduced systemic toxicity (published clinical evidence).
Differentiates HEPZATO from systemic therapies (e.g., immunotherapies like KIMMTRAK), enabling:
Delcath reported initial US launch revenues in 2023–2024, with:
5. Expansion of treatment center network (key volume driver)
HEPZATO is delivered only at certified centers, requiring infrastructure and training.
Delcath is actively expanding the number of US treatment centers, which directly correlates with revenue growth.
HEPZATO-KIT Recent Developments
In February 2026, Delcath Systems announced it submitted a new drug application (NDA) resubmission to the US Food and Drug Administration (FDA) for the HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System or Melphalan/HDS) seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM).
“HEPZATO-KIT Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of HEPZATO-KIT for approved indication like Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma in the 7MM. A detailed picture of HEPZATO-KIT’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the HEPZATO-KIT for approved and potential indications. The HEPZATO-KIT market report provides insights about HEPZATO-KIT’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current HEPZATO-KIT performance, future market assessments inclusive of the HEPZATO-KIT market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of HEPZATO-KIT sales forecasts, along with factors driving its market.
HEPZATO-KIT Drug Summary
HEPZATO-KIT is an FDA-approved (August 2023) liver-directed chemotherapy kit developed by Delcath Systems, indicated for adult patients with uveal melanoma featuring unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to bone, lymph nodes, subcutaneous tissues, or lung amenable to resection/radiation. It comprises melphalan hydrochloride powder for reconstitution (195 mg/vial) delivered via the proprietary Hepatic Delivery System (HDS), a percutaneous hepatic perfusion (PHP) procedure that isolates liver circulation, infuses high-dose melphalan directly into hepatic arteries for 30 minutes, filters blood via double-balloon catheter and hemofiltration cartridge to remove >90% of drug before systemic recirculation, and is administered every 6 weeks (up to 6 cycles) by trained specialists under a REMS program due to risks like bone marrow suppression, hypersensitivity, and hepatotoxicity. As an alkylating agent, melphalan cross-links DNA to inhibit cancer cell replication, achieving superior objective response rates (35.2% vs. 12.5%) and progression-free survival (9 months vs. 3 months) per the FOCUS phase 3 trial compared to standard care. The report provides HEPZATO-KIT’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the HEPZATO-KIT Market Report
The report provides insights into:
A comprehensive product overview including the HEPZATO-KIT MoA, description, dosage and administration, research and development activities in approved indications like Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma.
Elaborated details on HEPZATO-KIT regulatory milestones and other development activities have been provided in HEPZATO-KIT market report.
The report also highlights HEPZATO-KIT‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The HEPZATO-KIT market report also covers the patents information, generic entry and impact on cost cut.
The HEPZATO-KIT market report contains current and forecasted HEPZATO-KIT sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The HEPZATO-KIT market report also features the SWOT analysis with analyst views for HEPZATO-KIT in approved and potential indications.
Methodology
The HEPZATO-KIT market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
HEPZATO-KIT Analytical Perspective by DelveInsight
In-depth HEPZATO-KIT Market Assessment
This HEPZATO-KIT sales market forecast report provides a detailed market assessment of HEPZATO-KIT for approved indication like Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted HEPZATO-KIT sales data uptil 2034.
HEPZATO-KIT Clinical Assessment
The HEPZATO-KIT market report provides the clinical trials information of HEPZATO-KIT for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
HEPZATO-KIT Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
HEPZATO-KIT Market Potential & Revenue Forecast
Projected market size for the HEPZATO-KIT and its key indications
Estimated HEPZATO-KIT sales potential (HEPZATO-KIT peak sales forecasts)
HEPZATO-KIT Pricing strategies and reimbursement landscape
HEPZATO-KIT Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
HEPZATO-KIT Market positioning compared to existing treatments
HEPZATO-KIT Strengths & weaknesses relative to competitors
HEPZATO-KIT Regulatory & Commercial Milestones
HEPZATO-KIT Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
HEPZATO-KIT Clinical Differentiation
HEPZATO-KIT Efficacy & safety advantages over existing drugs
HEPZATO-KIT Unique selling points
HEPZATO-KIT Market Report Highlights
In the coming years, the HEPZATO-KIT market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The HEPZATO-KIT companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HEPZATO-KIT’s dominance.
Other emerging products for Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma are expected to give tough market competition to HEPZATO-KIT and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HEPZATO-KIT in approved and potential indications.
Analyse HEPZATO-KIT cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted HEPZATO-KIT sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of HEPZATO-KIT in approved and potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of HEPZATO-KIT? How strong is HEPZATO-KIT’s clinical and commercial performance?
What is HEPZATO-KIT’s clinical trial status in each individual indications such as Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HEPZATO-KIT Manufacturers?
What are the key designations that have been granted to HEPZATO-KIT for approved and potential indications? How are they going to impact HEPZATO-KIT’s penetration in various geographies?
What is the current and forecasted HEPZATO-KIT market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of HEPZATO-KIT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to HEPZATO-KIT for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is HEPZATO-KIT? What is the duration of therapy and what are the geographical variations in cost per patient?
1. First FDA-approved liver-directed therapy for metastatic uveal melanoma
HEPZATO KIT (melphalan with Hepatic Delivery System, HDS) received FDA approval in August 2023 for unresectable hepatic-dominant metastatic uveal melanoma (mUM).
It is the first and only liver-directed therapy approved specifically for this indication (Delcath press release, FDA approval notice).
First-mover advantage in a high unmet-need niche enables rapid adoption in specialized oncology centers.
Establishes strong positioning as a standard-of-care option for liver-dominant disease.
2. Strong clinical efficacy in liver metastases (primary disease driver)
In the pivotal FOCUS Phase III trial:
- Objective response rate (ORR): ~36%
- Disease control rate (DCR): ~74%
High response rates in the liver (key disease site) make HEPZATO particularly valuable →
Drives oncologist preference and clinical adoption.
3. Unique regional chemotherapy delivery system (HDS platform)
Uses a hepatic perfusion system to deliver high-dose melphalan directly to the liver, while filtering systemic circulation.
Allows higher local drug exposure with reduced systemic toxicity (published clinical evidence).
Differentiates HEPZATO from systemic therapies (e.g., immunotherapies like KIMMTRAK), enabling:
- Use in liver-dominant disease
- Combination or sequencing strategies
Delcath reported initial US launch revenues in 2023–2024, with:
- Increasing number of authorized treatment centers (ATCs)
- Expansion into major oncology institutions
5. Expansion of treatment center network (key volume driver)
HEPZATO is delivered only at certified centers, requiring infrastructure and training.
Delcath is actively expanding the number of US treatment centers, which directly correlates with revenue growth.
HEPZATO-KIT Recent Developments
In February 2026, Delcath Systems announced it submitted a new drug application (NDA) resubmission to the US Food and Drug Administration (FDA) for the HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System or Melphalan/HDS) seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM).
“HEPZATO-KIT Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of HEPZATO-KIT for approved indication like Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma in the 7MM. A detailed picture of HEPZATO-KIT’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the HEPZATO-KIT for approved and potential indications. The HEPZATO-KIT market report provides insights about HEPZATO-KIT’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current HEPZATO-KIT performance, future market assessments inclusive of the HEPZATO-KIT market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of HEPZATO-KIT sales forecasts, along with factors driving its market.
HEPZATO-KIT Drug Summary
HEPZATO-KIT is an FDA-approved (August 2023) liver-directed chemotherapy kit developed by Delcath Systems, indicated for adult patients with uveal melanoma featuring unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to bone, lymph nodes, subcutaneous tissues, or lung amenable to resection/radiation. It comprises melphalan hydrochloride powder for reconstitution (195 mg/vial) delivered via the proprietary Hepatic Delivery System (HDS), a percutaneous hepatic perfusion (PHP) procedure that isolates liver circulation, infuses high-dose melphalan directly into hepatic arteries for 30 minutes, filters blood via double-balloon catheter and hemofiltration cartridge to remove >90% of drug before systemic recirculation, and is administered every 6 weeks (up to 6 cycles) by trained specialists under a REMS program due to risks like bone marrow suppression, hypersensitivity, and hepatotoxicity. As an alkylating agent, melphalan cross-links DNA to inhibit cancer cell replication, achieving superior objective response rates (35.2% vs. 12.5%) and progression-free survival (9 months vs. 3 months) per the FOCUS phase 3 trial compared to standard care. The report provides HEPZATO-KIT’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the HEPZATO-KIT Market Report
The report provides insights into:
A comprehensive product overview including the HEPZATO-KIT MoA, description, dosage and administration, research and development activities in approved indications like Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma.
Elaborated details on HEPZATO-KIT regulatory milestones and other development activities have been provided in HEPZATO-KIT market report.
The report also highlights HEPZATO-KIT‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The HEPZATO-KIT market report also covers the patents information, generic entry and impact on cost cut.
The HEPZATO-KIT market report contains current and forecasted HEPZATO-KIT sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The HEPZATO-KIT market report also features the SWOT analysis with analyst views for HEPZATO-KIT in approved and potential indications.
Methodology
The HEPZATO-KIT market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
HEPZATO-KIT Analytical Perspective by DelveInsight
In-depth HEPZATO-KIT Market Assessment
This HEPZATO-KIT sales market forecast report provides a detailed market assessment of HEPZATO-KIT for approved indication like Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted HEPZATO-KIT sales data uptil 2034.
HEPZATO-KIT Clinical Assessment
The HEPZATO-KIT market report provides the clinical trials information of HEPZATO-KIT for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
HEPZATO-KIT Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
HEPZATO-KIT Market Potential & Revenue Forecast
Projected market size for the HEPZATO-KIT and its key indications
Estimated HEPZATO-KIT sales potential (HEPZATO-KIT peak sales forecasts)
HEPZATO-KIT Pricing strategies and reimbursement landscape
HEPZATO-KIT Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
HEPZATO-KIT Market positioning compared to existing treatments
HEPZATO-KIT Strengths & weaknesses relative to competitors
HEPZATO-KIT Regulatory & Commercial Milestones
HEPZATO-KIT Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
HEPZATO-KIT Clinical Differentiation
HEPZATO-KIT Efficacy & safety advantages over existing drugs
HEPZATO-KIT Unique selling points
HEPZATO-KIT Market Report Highlights
In the coming years, the HEPZATO-KIT market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The HEPZATO-KIT companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HEPZATO-KIT’s dominance.
Other emerging products for Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma are expected to give tough market competition to HEPZATO-KIT and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HEPZATO-KIT in approved and potential indications.
Analyse HEPZATO-KIT cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted HEPZATO-KIT sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of HEPZATO-KIT in approved and potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of HEPZATO-KIT? How strong is HEPZATO-KIT’s clinical and commercial performance?
What is HEPZATO-KIT’s clinical trial status in each individual indications such as Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HEPZATO-KIT Manufacturers?
What are the key designations that have been granted to HEPZATO-KIT for approved and potential indications? How are they going to impact HEPZATO-KIT’s penetration in various geographies?
What is the current and forecasted HEPZATO-KIT market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of HEPZATO-KIT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to HEPZATO-KIT for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is HEPZATO-KIT? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
30 Pages
- 1. Report Introduction
- 2. HEPZATO-KIT Overview in approved indications like Liver metastases; as well as potential indication like Liver cancer and Cholangiocarcinoma
- 2.1. Product Detail
- 2.2. HEPZATO-KIT Clinical Development
- 2.2.1. HEPZATO-KIT Clinical studies
- 2.2.2. HEPZATO-KIT Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
- 3. HEPZATO-KIT Competitive Landscape (Marketed Therapies)
- 4. Competitive Landscape (Late-stage Emerging HEPZATO-KIT Therapies)
- 5. HEPZATO-KIT Market Assessment
- 5.1. HEPZATO-KIT Market Outlook in approved and potential indications
- 5.2. 7MM Analysis
- 5.2.1. HEPZATO-KIT Market Size in the 7MM for approved and potential indications
- 5.3. Country-wise Market Analysis
- 5.3.1. HEPZATO-KIT Market Size in the United States for approved and potential indications
- 5.3.2. HEPZATO-KIT Market Size in Germany for approved and potential indications
- 5.3.3. HEPZATO-KIT Market Size in France for approved and potential indications
- 5.3.4. HEPZATO-KIT Market Size in Italy for approved and potential indications
- 5.3.5. HEPZATO-KIT Market Size in Spain for approved and potential indications
- 5.3.6. HEPZATO-KIT Market Size in the United Kingdom for approved and potential indications
- 5.3.7. HEPZATO-KIT Market Size in Japan for approved and potential indications
- 6. HEPZATO-KIT SWOT Analysis
- 7. Analysts’ Views
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
- 12. Report Purchase Options
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
